NAV

Fluocortolone

Identification

Summary

Fluocortolone is a glucocorticoid used topically for localized skin reactions and also orally for systemic use.

Generic Name
Fluocortolone
DrugBank Accession Number
DB08971
Background

Fluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
3D
Similar Structures
Weight
Average: 376.4617
Monoisotopic: 376.204987621
Chemical Formula
C22H29FO4
Synonyms
  • Fluocortolona
  • Fluocortolone
External IDs
  • SH 742
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofSkin inflammation••••••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbametapirThe serum concentration of Fluocortolone can be increased when it is combined with Abametapir.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Fluocortolone.
AbemaciclibThe metabolism of Abemaciclib can be increased when combined with Fluocortolone.
AcalabrutinibThe metabolism of Acalabrutinib can be increased when combined with Fluocortolone.
AcarboseThe risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Acarbose.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
SCHERIPROCT N CREAMFluocortolone (1 MG/1G) + Lidocaine (20 MG/1G)CreamTopicalบริษัท ดีเคเอสเอช (ประเทศไทย)2020-05-21Not applicableThailand flag
ULTRALAN POMAT, 10 GRFluocortolone (0.25 %) + Fluocortolone caproate (0.25 %)OintmentTopicalBAYER TÜRK KİMYA SAN. LTD. ŞTİ.2020-08-142017-12-19Turkey flag
ULTRALAN POMAT, 20 GRFluocortolone (0.25 %) + Fluocortolone caproate (0.25 %)OintmentTopicalBAYER TÜRK KİMYA SAN. LTD. ŞTİ.2005-05-172017-12-19Turkey flag
เชริพร็อค(R) เอ็นFluocortolone (1 MG) + Lidocaine (40 MG)SuppositoryTopicalบริษัท ดีเคเอสเอช (ประเทศไทย)2020-06-01Not applicableThailand flag

Categories

ATC Codes
D07AC05 — FluocortoloneD07CC06 — Fluocortolone and antibioticsD07BC03 — Fluocortolone and antisepticsS01CA04 — Fluocortolone and antiinfectivesD07XC05 — FluocortoloneH02AB03 — FluocortoloneC05AA08 — Fluocortolone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / Halogenated steroids / 3-oxo delta-1,4-steroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Alpha-hydroxy ketones / Secondary alcohols / Cyclic ketones / Cyclic alcohols and derivatives
show 5 more
Substituents
11-beta-hydroxysteroid / 11-hydroxysteroid / 20-oxosteroid / 21-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 6-halo-steroid / Alcohol / Aliphatic homopolycyclic compound / Alkyl fluoride
show 19 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
65VXC1MH0J
CAS number
152-97-6
InChI Key
GAKMQHDJQHZUTJ-ULHLPKEOSA-N
InChI
InChI=1S/C22H29FO4/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-21(15,2)20(13)17(26)9-22(14,3)19(11)18(27)10-24/h4-5,7,11,13-14,16-17,19-20,24,26H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20-,21+,22+/m1/s1
IUPAC Name
(1S,2R,3aS,3bS,5S,9aR,9bS,10S,11aS)-5-fluoro-10-hydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one
SMILES
[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C

References

Synthesis Reference

U.S. Patent 3,426,128.

General References
Not Available
PubChem Compound
9053
PubChem Substance
310264934
ChemSpider
8701
RxNav
4463
ChEBI
135581
ChEMBL
CHEMBL251634
ZINC
ZINC000004213353
Wikipedia
Fluocortolone

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet
CreamTopical
Tablet20 mg
TabletOral5 mg
OintmentTopical
SuppositoryTopical
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)180-182U.S. Patent 3,426,128.
Predicted Properties
PropertyValueSource
Water Solubility0.0339 mg/mLALOGPS
logP2.09ALOGPS
logP1.97Chemaxon
logS-4ALOGPS
pKa (Strongest Acidic)13.84Chemaxon
pKa (Strongest Basic)-0.23Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area74.6 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity101.47 m3·mol-1Chemaxon
Polarizability40.14 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-052f-0009000000-346900cd4ed7da202f08
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00os-0009000000-b6014559d4a039401bed
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-054o-0129000000-0751fcb6367e668fb20e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00mn-0019000000-16590019f34ea1fe157a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0032-0921000000-0b54f1104d849520aa83
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0fba-0019000000-a93b37ed6c78ca1c8d52
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-193.78029
predicted
DeepCCS 1.0 (2019)
[M+H]+195.504
predicted
DeepCCS 1.0 (2019)
[M+Na]+202.26662
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
  2. Grayson L., Crowe S., Hope W., McCarthy J., Mills J., Mouton J., Paterson D., Paterson D. and Pfaller M. (2010). Kucers' the use of antibiotics (6th ed.). Taylor and Francis Group. [ISBN:978-1-4441-4752-0]
Details2. Cytochrome P450 3A5
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]

Drug created at June 09, 2014 16:27 / Updated at June 12, 2021 10:54